Combining PI3K/AKT/mTOR inhibitors with standard chemotherapy not only reduces chemotherapy resistance but has also demonstrated significant sensitization effects in preclinical studies on cervical cancer and liver cancer [151]. The gene discussed is AKT1; the disease is cervical carcinoma.